HUE031582T2 - Dihidropiridon mint xia-faktor inhibitorok - Google Patents

Dihidropiridon mint xia-faktor inhibitorok Download PDF

Info

Publication number
HUE031582T2
HUE031582T2 HUE13747624A HUE13747624A HUE031582T2 HU E031582 T2 HUE031582 T2 HU E031582T2 HU E13747624 A HUE13747624 A HU E13747624A HU E13747624 A HUE13747624 A HU E13747624A HU E031582 T2 HUE031582 T2 HU E031582T2
Authority
HU
Hungary
Prior art keywords
oxo
methyl
mmol
íció
carbamate
Prior art date
Application number
HUE13747624A
Other languages
English (en)
Inventor
Wu Yang
James R Corte
Paul J Gilligan
Donald J P Pinto Pinto
William R Ewing
Yufeng Wang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HUE031582T2 publication Critical patent/HUE031582T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (2)

  1. i < K4çht KKtwu K «jjv'û·'«? (Vurs
    (VS H) WgJÎ «BSak UtsrepUEOn*«]*. tfttiMne*«, $V»g>··«f jfep#S*Ä:«$». ·>#S$i lÿ'iîrîi Λ iÎiggsîk'îï'sü: ki vàtem s kôvti.ksîèk kôsàl.
    ....... «sx-axkAs kXés; &amp;- &amp;jsgkSi««üi kï vus vîîîssjS’vS 4kdv<ak*»ôk koaxs: H, .kkStoxk üH Cj^siki-S; íug^sífesssi jh v-s» v-âtaam s kSye&amp;eg:dkkkxôfc H »s Séïfssii; II* fUg$?>!er&amp;> ki vas. véhmv&amp; s fcdv«tbsssôk tcSàfsl: H, OFx R OC;..< »ikü, w» CN? t$* fúggstterM kî va« vilasKva a köv«sk<.v.ßk kOaisl' H, F. O. à$ Bk R'- MggstSssiLk'i van váfa**íva a kïsvaîkciôk kSiUI: U H F.&amp; Ik** ft%^ÎSRÔSki vas, víüa&amp;Kíva j kovc.tk.cf.Ak kôiïil: H< P. i? CS.
  2. 1.- As vis'ïsks vegyülik sh;:=S: gvMi.A ki ?M klJssAkk s MV§ikàk§k:feSIpl:
    έ»
    A A 2. %#nypf$t sasrisís vagyöfeíj srcicSysck k*p;«S* CÀX}'
    ίΙΧ; v»g^ sterns?«, fÿ-%^faté»j8ciîkg-.5àlb^dha?ô. sàj-â, < ah©i; R' Figgskls.MF k; vsa válásaivá a kúvriksSk kiMil: K O taeilU R* iïùsiéçgyik iîSàfïffïiuSâiibàï! -fli^g<stîîtwôj ïc= v&amp;n visas?} ys s fcővsfisesök ksO-.sli H A IskUVkíí; R’ ks vaa vilassava « RMskkasdk köss;: li OH. F. OC s .< aikii, às< CN. R5'5 ïVsg§««'S''â! ki vas; yàitwtva s VíH-f-isf >fsk kftMl· H F Pi H F%î. â::S Sïg&amp;eîteil kl va« választva.-. k\H-s.4k#?6k kik«l· H és F; O R* Pi«gRîkï;Ü! ks va« vüssafva s Rövíikei&amp;k kivüä: H. F. 4* Cl. 4. A 3 Igiwypoaf m*îîssîi vcgySkv ahol R4 H; R** AggssMMi kl vat: và;s.s->'.i>'s s kOvcíkíaök kskiSl· H. K 4' 4s. IM F; 4s R* i&amp;ggaïR'f.î'O k; vsa visasse fs a RÓVískííAk M si a'. If. I. sA Ci. $< Â'fi P ifsk'ïvjf'Sïitsseïix'iP vs^stâei» ajsaly k.vv&amp;K vkissssiv'S s kFvRkR&amp;î&amp;kMIssllè.»ss>^ôfîb6]î· MôîII ^HOöRj4S)-l4'!4'!5'ki;;íP.PskA:}s>ffavsl)'F-a}S0'l .ï.S.i>-iKfr;fii.ifirsjgs3j-sv.0fi'i 'il)' iO síicisl ^^ s;as>k;î4'dîSï.&amp;;noskfÿ1 13 >.l (F 'is··:«!,Risk*- > 1:4.4.4,6,1S.; ;4::c:fáínA'slAsrk;sfyÁ; Sisal A f f U5 IC; 4 As -1 à - F * ;,ö Wi» ? k;<kr g Mc·· Ma R &amp; os*- ; .a ,5.4· ísfísahídf opKidass- Mil ; 4-sîiiâli-R 14-iR&amp;^RîCikfei.;4.k1.0; íissOS:SíiakR-ií s^îPAA. P5 s 7-Μ^νίΜ-:; iksíMaM, S4MS .IV-IC 10R.H^is^4'(4.(J-|:ïdr-Stf'-àîR«{wRiidi)'<P!>Ko-s<2>^d~'Îîîfaïïidf<'î'ïSïifîiî!-i*n]»Î0s'fs}iss!kdk sVXO R}16,i&amp;-tn8£saidk!i>(i > <· ; .0"' iok-aàakaM 171.2,4.6.13*' SS}'p«k*aa*5»R]k»i$?a«i3i. Meg; A' l(íö.43í?4FFFr.P{J.kUkíC.6''sl.!ii'aí'íí'lVT:Fk6~as!.ü-; > : .P -istf^shisi;;>psí-ísisíi- à j |. f OveiaMk·· gsg'SJMPMïàïg^nOkiôl ;3 3.1.0'' 'RS'SsaisiisfcsAi skf.kAkJkikRmakaA'srRsss.b&amp;iissR, Siesil N ::i'IÔR,PïRVVFr4-PÎ-k^d,PdSî1aôî1sîiiU-fF;>ao-'ii2,3.6 iairahldropinsK«·Ml··iO-rasaM M'txsM, iS'ii';;;es;:s;.Ml;g ; 7 .> ; k'^jSskisiAkss·· P Ï kgRk.kJ kg;efííMs;.-?<-;;Rs:fá<s;sAr Metis MfCIOsMAJ; 54·Γ4'(,'Α)6ί .'? fí'ddixiíss'Maí.i-b síxO' I.2J.4 jeirMMwganM;! I síi 12 hMrexi-I ô.ïÎ:s"4l"R'>>asj-R.Uk'd;.wk",çsl-'ls.!| s.3.3 1.0" inas'istSsAs'U |%2,4χ·&amp;,15,174wss4s-5'll!kSäbäiTi4i,. Mekst MR IAS). |4.|ís.(Skkjy>;v;, ,Fk!4f'-2.O'K.'!'1»PslrS'*sg-1,2 .FF-tss'shisk'ogkldls··,· I -ti]-$-»*A· Μ&amp;,Ι ll'i^SJS&amp;iiktkloj; 13 2.1 Xè Ct.^isskkaM Ml,,?.4,6.5 3(1 M-pvsaiaga-.MflkssXsassa . Mä Uö*.* * SH 4· Ι*(*Μ*·2· 0 ί 4 J *·^®44^}4ί&amp;ί-· * -4-16- instill 4 j ' ·οΐ'’ 1 ·. > ^.16,1^-atrfcikklina Ö4'j*»«»Hl7U.4A1* ^(iSSJâS» Ι4.(4η>Ι^34^μΑα8; ^-oar- U.?^tew#îi<iN)p5Hd«»*!j -i*jl· i&amp;^iÄ ims^-πΑ ^ t.te'í! ^[{íOiía^Sí' Η'4 5 j^fsJïî^^^l^-^ tïrii'ahidiXïpLridiîi í ^rî-ÎÎÎÇtosî- 10«! « ^ * lo ***tri ' * »' '' " ^ '*^‘ ' 4 *' '*1 5"!< UxaN' «*· 1 Mí!,j *>3'^»íí&amp;{,^í<,5>«'lfÍ!fí'“**)?íf- ^8.|Míá«8tr«'>k!o|í kU 0' Wáote*H^R4Al5.1 ' ^ssèa-5-ülk^«; Uox\ .Vs-<iój|,i4^-H44 <3"k^,€*^^feÄt}V0-oso-Ki,5,S-508Ä^öiii#!'^^*iö'if>s«ül-OfcH^M^fcl^Wxio^l« K0'Vi»4»k*O{ia2^A^{l^P<«5S^S"ÍI^^· |>í«si Λ'Ί( 5¾) . I <s - i'^·-i^-'-kl^r-'^-iö- ií ΐ í1««r^r fts */-* ' ox«^.i:;^¥i.l^fcüíy^ííÍF<?í^íí,iiiilíSíi::í ' ΐ| 1 -1 Ö-sseíil^- «K^-as?g-íiísa«t^;kíí>r13.5. í Oa5?. 1"-l^xs^s- ívMd <v-fí Sóá\ · 4Ä}':4- ( A •{k-bb'-2,&amp;4>nao?í«8$0'6*<>xov i.2.3,$-ísfcshíáíOpsíi<Uxi- ; -ííHÖ-ímíí.· 9^ö*<s*B» 1"?.I«'«iÂsotTîC'-kio^ B.2 ! "iókö«Míka^Ml M^tií N-! Î *iS. 3 4S} ' i 4 Í4-î ,-<^>4, ϊ ii'disis^íivskka U .4 S .0'* ' {£$M^$rl§^ .'"ht?*«é$ï-.$-ïsj;k8ftîiMt}à$ç Μδϋΐ K4(iaRa4S>44-{4-44r»k«#·? !-Ä^I>^*SiS'! ,2ν?Λ· Msöí H-{{ Í8H, 1454 |444^1^V^Ä-l^a^»^>4^xo«1 434täSÄ4*s4sd&amp;· i 4] . i g.. ®^&amp;ô*5ê^.ïiM&amp;iæ|«ôfe^ Sroxssfeî 6«ds8x*iri«&amp;Mí'3-5-1 .^5m«^4C^^«5»^-4í*xoéö-S 4!|*f|(*Ä ®4#4^»íé#Wl44l^ (KiRJ4S}'H-H-0-4Ü6r. 3 >Míferi»nü}4-óxö4 J ,3 .R^Âîàrs^RiâîR-i-y S: àLsasîïfcsîsiSo] Ι33Χ8^^3ϊ8^«·ίρ^^Ϊ^Ϊ%^Μίέ»*Ιδ··ίΐ»ί!»ΪΟ>ο&amp;(ί^ 1st ífS.S5-:ató<:skb[ B4.t Ç* $i,%Αφ, ' % W 4sstsbn -Sus ikarksssis; Μβ»ί A/-f(l0/?tJ4,S)--Í4-.J4-(3«5dóí*2,6'á''fi«í“4wii1}-#>-osi>-í,3i?\6-íí,s«>líidroplríá»a-: 4M KsMîæ;... i 4jrxiîiM4>X;>S: î 44»2asrM4ö;' i 4. J S .0'!'?pwss<kkft' i ( : ¢),2,4 fi. ! S, I ? - bc ». Mr - 54 }kss b arrakí ; M?«l Aj-fCîÔR.l4Si-i4.{4_(3-jçâôf-.'?.é-«^li<'-ï,&amp;}!iO'^<-'i^s,-'-'?.S»4'fe‘SraiRfkiîpîKdb*t*î!|‘‘îÔ«mî!l» 0H»o*8*âK»tïfcâcb( B.3.I -Ô*:Ît»sim5cka-Hi 9) 4 >4.6. JS.I? -kíttó· 5- si MM; N-fí'ÍÖS 4RM4MM4M444;í4MM?:}4-rí.;>·;4Λ4;;'ΐΜ5Μ;φ;π4?Μ-:ΜΜ-^Μ].. 5-oxö-H,iÄ-<i{i}KstKi.iklfi t J θ' jsu-síi,* M t !4 '4,0 > 1 hv>.4.n-''i!\Âiw. Mo.äil N-4;ök ME).;<i~;MJ-k!6r44-&amp;4>iOífc4í).fcvíí><jM.43.6*?^^«df opinai«·Î4}-HMrMM £-0**>· SJ RdtoinoRfcJ ii.).j .{4 ’jtâcaaiîeka' U 19).2.4 4. i .1 î ?· MxsMM-RIMMssM; N·Î{Ï-ÎS).'.«H*-* 4%Md#^<!i i3 J. i.O* vjaoaas*k*í (SPX.2Í ?*J,5 J3,i 7'te*èn»34ljk«rfe*«i&amp;; Mb$: bi>£fl4$} 44.t4-i^kW'?Jyi&amp;iÄÄlyMy4>d5&amp;^ !4^{U^-<«0“S?-jiistsK(lbö ' 3 '; .θ’ ·]«οί»^«- i ϊ. i&amp;U,4&amp;i ί\ 1 '? -h^ae^S'iiltebamáí. &amp; ®y&amp;$y&amp;i#ièmà fcossg*«}«^ «η#4ν «μ*»!«?«* a? \ *5. igèKypoaiok bitnyik» *a*B|Äy«gy^:«k' Sî&amp;Âogyoi. vagy ô%ïî ës p^ysAiîôsi^jlsg 4p?p#tó bortafoKtyagov vagy b%0§s^ft, % -M- b&amp; i0i^mmU t>ázmfyú$ ψ^ΜΜί vagySt«» vagy annak eatapeöfeomeí*, Ut«lomer»v vagy 0é0sa&amp;x$mii®eig sí^sábaaS MJa ysgy a? 5; igénypont saaHfi« J$mpo?.óoé &amp;lb**>»li4*«r* győgys>'«fk«nt k. :M· f·#. Igèîiyp#sïâïk bátaseiyikí 8»»Ιλ:α vegyfeiet« '•agy msak «wtPMxorere, iauwt»»«, vagy <0ibp4i#ó séjs v&amp;gy « &amp; ^fénypont s«?*»o kompozíció fcFnaæsiïàiâsr» tbrpmfeoeasMiku? iißMkoeMg Sce*ete$i?Tsi 4vvaj^:|»»4?«stíaá*»;.: % A&amp; ívsgytüervagy keaajKsiÄ á&amp;í kWMfa&amp;ßtäSä» ki va© y|k;^|y4 anéfiá* «anüemcviiro khpatabo^mfeoliksa ïaœfeSaesasâ&amp;vic,. vés*á&amp; «aïdksæsaiifcrk îhnïaêôeaîbîxUkiua rc«ddle«ességak, gfeivkiMiw vagy p-ílktislis kedagáa íps^aöm-s^gf.í köatU.. íSi Λ 8« ipssçoMï 3z«:»o vegyâiet vagy köxapOxid«. , absd » St: VSsy váks&amp;vs sz Instabil aegonu aksu koronát» sain&amp;ówa. »I^arfíbröláeik: siÿeomdffe isÉfteos, isÄSlfeaa tsefc*œiàs tséass* stroke, *tb«os<>kroaSs. pan&amp;oáli«· oklüásív srsbrilils betegség, vénás tîa-ïiflbôïis, siéiyvgnàs íhroí-íbór-y O^ptsfenphicböls, artériás oa*boiiz.rassj 'fceroeáHás soeoàôs thmatbos'.s.. cöíehraKx artariaiis únwob:«K ocrisbrsläs ctnhnlixnoja, ve·«} esífekesmisi, tSáb etnbnbMttv» e* «vos; fsapUfîïtàswî.voi'bêl, bm'íxk-sésskbóK vsjí>· eljárásukból kbvrikozè ík'Oftíhosiv, aJH&amp;îyektiÿÎ vet '.sí; kitïîv« iw.««r5dgcs fc'âk'îRcîf atneíy ihönásc"*',&amp;s sagst κ!&amp;
HUE13747624A 2012-08-03 2013-08-02 Dihidropiridon mint xia-faktor inhibitorok HUE031582T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261679197P 2012-08-03 2012-08-03
US201361786992P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
HUE031582T2 true HUE031582T2 (hu) 2017-07-28

Family

ID=48949289

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13747624A HUE031582T2 (hu) 2012-08-03 2013-08-02 Dihidropiridon mint xia-faktor inhibitorok

Country Status (26)

Country Link
US (2) US20140038969A1 (hu)
EP (1) EP2882734B1 (hu)
JP (1) JP6082462B2 (hu)
KR (1) KR20150038369A (hu)
AR (1) AR093759A1 (hu)
AU (1) AU2013296258A1 (hu)
BR (1) BR112015002293A2 (hu)
CA (1) CA2880898A1 (hu)
CY (1) CY1118450T1 (hu)
DK (1) DK2882734T3 (hu)
EA (1) EA025392B1 (hu)
ES (1) ES2605824T3 (hu)
HR (1) HRP20161378T1 (hu)
HU (1) HUE031582T2 (hu)
IL (1) IL237012A0 (hu)
LT (1) LT2882734T (hu)
MX (1) MX361370B (hu)
PL (1) PL2882734T3 (hu)
PT (1) PT2882734T (hu)
RS (1) RS55581B1 (hu)
SG (1) SG11201500270RA (hu)
SI (1) SI2882734T1 (hu)
SM (1) SMT201700003B (hu)
TW (1) TW201410666A (hu)
UY (1) UY34959A (hu)
WO (1) WO2014022766A1 (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
SI2766346T1 (sl) 2011-10-14 2017-05-31 Bristol-Myers Squibb Company Substituirane tetrahidroizokinolinske spojine kot faktor xia inhibitorji
WO2013055984A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2579832T3 (es) 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa
SI2906551T1 (en) 2012-10-12 2018-05-31 Bristol-Myers Squibb Company CRYSTALINOUS FORMATS OF XIA FACTOR INHIBITOR
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
JP6464176B2 (ja) * 2014-01-31 2019-02-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環
NO2760821T3 (hu) * 2014-01-31 2018-03-10
US9944643B2 (en) * 2014-02-11 2018-04-17 Merck Sharp & Dohme Corp. Factor XIa inhibitors
US9663527B2 (en) 2014-02-11 2017-05-30 Merck Sharp & Dohme Corp. Factor XIa inhibitors
JP6526796B2 (ja) * 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｘｉａ阻害剤であるジアミドマクロ環
NO2721243T3 (hu) * 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
EP3310777B1 (en) 2015-06-19 2019-10-09 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors
CN107849026B (zh) 2015-07-29 2021-01-01 百时美施贵宝公司 携带烷基或环烷基p2′部分的因子xia大环抑制剂
CN114874222A (zh) 2015-07-29 2022-08-09 百时美施贵宝公司 携带非芳族p2,基团的因子xia新大环
US10344039B2 (en) * 2015-10-29 2019-07-09 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use
JP6892858B2 (ja) * 2015-10-29 2021-06-23 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 第ＸＩａ因子阻害剤
JP2019507167A (ja) * 2016-03-02 2019-03-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害活性を有するジアミド大員環
TW201808908A (zh) 2016-08-22 2018-03-16 美商默沙東藥廠 因子XIa抑制劑
KR20220002966A (ko) 2019-04-16 2022-01-07 메드샤인 디스커버리 아이엔씨. XIa 인자 억제제로서의 거대고리 유도체
JP7286001B2 (ja) * 2019-07-23 2023-06-02 メッドシャイン ディスカバリー インコーポレイテッド 第ＸＩａ因子阻害剤としての大環状誘導体

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
EP1192135A2 (en) 1999-06-14 2002-04-03 Eli Lilly And Company Serine protease inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
CA2726702A1 (en) 2001-09-21 2003-04-03 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7459564B2 (en) 2005-01-13 2008-12-02 Bristol-Myers Squibb Company Substituted biaryl compounds as factor XIa inhibitors
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
WO2007070816A2 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Thiophene derivatives as factor xia inhibitors
JP5225098B2 (ja) 2005-12-14 2013-07-03 ブリストル−マイヤーズ スクイブ カンパニー 第ＸＩａ因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ
US8163749B2 (en) 2005-12-14 2012-04-24 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2008076805A2 (en) 2006-12-15 2008-06-26 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
PE20081775A1 (es) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
AR067329A1 (es) 2007-06-13 2009-10-07 Bristol Myers Squibb Co Analogos dipeptidos como inhibidores del factor de coagulacion
ES2380648T3 (es) 2008-03-13 2012-05-17 Bristol-Myers Squibb Company Derivados de piridazina como inhibidores del factor XIA
CA2789622C (en) * 2010-02-11 2018-04-03 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
SI2766346T1 (sl) 2011-10-14 2017-05-31 Bristol-Myers Squibb Company Substituirane tetrahidroizokinolinske spojine kot faktor xia inhibitorji
ES2579832T3 (es) 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa
WO2013055984A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
IN2014CN04676A (hu) 2011-12-21 2015-09-18 Ono Pharmaceutical Co
JP2015083542A (ja) 2012-02-08 2015-04-30 大日本住友製薬株式会社 ３位置換プロリン誘導体
GB201209138D0 (en) 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds

Also Published As

Publication number Publication date
MX2015000919A (es) 2015-09-21
PT2882734T (pt) 2016-12-09
RS55581B1 (sr) 2017-06-30
WO2014022766A1 (en) 2014-02-06
CY1118450T1 (el) 2017-06-28
DK2882734T3 (en) 2017-01-30
CN104520289A (zh) 2015-04-15
JP6082462B2 (ja) 2017-02-15
US9376444B2 (en) 2016-06-28
US20150166550A1 (en) 2015-06-18
SG11201500270RA (en) 2015-03-30
AU2013296258A1 (en) 2015-03-19
EA201590284A1 (ru) 2015-05-29
EP2882734B1 (en) 2016-10-12
EP2882734A1 (en) 2015-06-17
IL237012A0 (en) 2015-03-31
HRP20161378T1 (hr) 2016-12-02
JP2015524443A (ja) 2015-08-24
TW201410666A (zh) 2014-03-16
BR112015002293A2 (pt) 2017-07-04
UY34959A (es) 2014-01-31
ES2605824T3 (es) 2017-03-16
EA025392B1 (ru) 2016-12-30
KR20150038369A (ko) 2015-04-08
CA2880898A1 (en) 2014-02-06
AR093759A1 (es) 2015-06-24
MX361370B (es) 2018-12-05
LT2882734T (lt) 2016-12-12
PL2882734T3 (pl) 2017-05-31
SMT201700003B (it) 2017-03-08
SI2882734T1 (sl) 2017-01-31
US20140038969A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
EP2882734B1 (en) Dihydropyridone as factor xia inhibitors
EP3089979B1 (en) Pyrimidinones as factor xia inhibitors
US9951071B2 (en) Dihydropyridone P1 as factor XIa inhibitors
US9108981B2 (en) Cyclic P1 linkers as factor XIa inhibitors
US9403774B2 (en) Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906552B1 (en) Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP3189047B1 (en) Diamide macrocycles that are fxia inhibitors
EP3310777B1 (en) Diamide macrocycles as factor xia inhibitors
US10752641B2 (en) Diamide macrocycles having factor XIa inhibiting activity
EP3868753B1 (en) Factor xia macrocyclic inhibitors bearing a non-aromatic p2&#39; group
US20190144393A1 (en) Factor xia macrocycles with novel p1 groups